Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) - Tao Levy at Deutsche Bank

Berger stressed that these aren't errors in technique and that the issue "was related to the implant design itself.". Deutsche Bank analyst Tao Levy said this could be a "potentially significant issue" for Zimmer and also a positive for rivals Stryker Corp ( SYK ) and Johnson & Johnson ( JNJ ). The orthopedics conference has also featured scrutiny of so called "metal on metal" hip implants, which use metal surfaces on both the ball and socket portions, amid some safety concerns. These aren't new concerns to surgeons, but they have been aired out in recent news reports, and analysts indicated Thursday that doctors will ramp back on using these parts. The metal hips are popular for perceived durability, but doctors also have hips with ceramic and plastic surfaces at their disposal. 

Johnson & Johnson (JNJ) - Tracy Staton at Fierce Pharma

Some newly released court documents suggest that Johnson & Johnson was leaning heavily on the geriatric market to boost sales of its atypical antipsychotic Risperdal at a time when federal regulators were warning the company against claiming the drug was safe and effective in elderly patients, Bloomberg reports. . The documents, made public after Bloomberg asked a judge to unseal them, show that J&J was pushing to expand use of the drug beyond its schizophrenia indication. "Schizophrenia represents only 35 percent" of antipsychotic scrips, one executive at J&J subsidiary Janssen wrote in an internal report. 

Johnson & Johnson (JNJ) - Bill Nygren at Oakmark

a discrepancy that won't last forever. Johnson & Johnson, for example, trades at a P/E of 13, compared with around 19 for the S&P, says Bill Nygren, co manager of the Oakmark Fund. What's more, JNJ's 3.1% dividend is more than the yield on five year Treasuries 

Johnson & Johnson (JNJ) - Ian Hunter at Goodbody Stockbrokers

The EMEA halted the approval process solely on concerns over good clinical practice during the tests Basilea is seeking damages from J&J, which could be at least €66m, Goodbody analyst Ian Hunter said yesterday in a note to investors 

Johnson & Johnson (JNJ) - Timothy Anderson at Sanford C. Bernstein

I think, to be fair Jim Edward's (B|Net Pharma's) latest on the topic. Tim Anderson of Sanford Bernstein probably meant handing off substantially all of the (legacy Schering Plough) Consumer Health business franchises to Johnson & Johnson, in return for retention of at least some of the non US distribution rights to Remicade and Simponi As Tim (and Jim) well know, the wrinkle here is the amount of overlap between J&J's consumer health offerings, and the New Merck's set of offerings It would be more than a notion to try and clear this through the FTC's Hart Scott (antitrust) review staffers In any event, it is a n interesting thought, per Jim Edwards: 

Johnson & Johnson (JNJ) - Christopher Raymond at Robert W. Baird & Company

The anemia drugs are used for kidney disease and cancer, but studies linking them to shortened survival in some cancer patients, as well as to heart problems at high doses, have decimated sales RW Baird analyst Chris Raymond wrote recently that the number of cancer patients taking the drugs — known collectively, along with Johnson & Johnson (JNJ)'s Procrit (epoetin alfa), as Erythropoiesis Stimulating Agents (ESAs) — fell from 60 percent in 2007 to just 29 percent today But ESAs got a little (relatively) good news this week The FDA approved a plan to monitor use of the drugs in cancer , and it wasn't as harsh as it could have been It requires doctors to get trained on the risks and benefits of ESA use, and to counsel prospective patients and provide them with a medication guide 

Johnson & Johnson (JNJ) - 24/7 Wall Street

ConocoPhillips (NYSE: COP), Exxon Mobil Corp (NYSE: XOM), Becton, Dickinson and Company (NYSE: BDX), Johnson & Johnson (NYSE: JNJ), Gannett Co (NYSE: GCI), Moody's Corp (NYSE: MCO), Wal Mart Stores Inc (NYSE: WMT), Procter & Gamble (NYSE: PG), United Health Group (NYSE: UNH), Wellpoint Inc (NYSE: WLP), Wells Fargo & Co (NYSE: WFC), Sun Trust Bank (NYSE: STI), Iron Mountain (NYSE: IRM), Republic Services Inc (NYSE: RSG), Norfolk Southern (NYSE: NSC), Union Pacific Corp (NYSE: UNP), and NRG Energy (NYSE: NRG) were most of the changed positions at Berkshire Hathaway We have given color on each and predictions of which stocks Buffett will probably add to or cut further Media outlets spent much time discussing the drop of ConocoPhillips (NYSE: COP) down to about 377 million shares 

Johnson & Johnson (JNJ) - Zacks Investment Research

For quite some time, anemia drugs developed by Amgen ( AMGN , Analyst Report ) and Johnson and Johnson ( JNJ , Analyst Report ) have been under the US Food and Drug Administration (FDA) scanner. Recently, the agency announced a new safety plan for both the companies related to the use of these drugs, also known as erythropoiesis–stimulating agents (ESAs), on cancer patients ESAs are approved for the treatment of anemia that might arise out of kidney failure from certain kinds of chemotherapy 

Johnson & Johnson (JNJ) - Jan Wald at Noble Financial Group

Despite all the recent negative headlines related to Johnson & Johnson JNJ N , there may, in fact, be relief on the horizon for the company's suffering investors Jan Wald, analyst at Noble Financial Group, believes good times lie ahead for the company's stock performanced and, for his part, has a buy recommendation on the stock with a price target of $76, compared to Wednesday's $6270 closing price 

Johnson & Johnson (JNJ) - Larry Biegelsen at Wells Fargo

Wells Fargo analyst Larry Biegelsen said he worries the enormous payout to J&J "will hamper Boston Scientific's ability to supplement its pipeline with bolt on acquisitions, which is an important avenue for enhancing a company's pipeline"